All In Biotech

Drug Trial Radar · NCT04875026

Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial

Last checked: Nov 20, 2026Latest source record: Sep 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Feb 16, 2021

Primary completion

Jan 31, 2022

Study completion Jan 31, 2022

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
Collaborators
Clinact
First posted
May 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transient local skin reactions with topical Actinic Keratosis treatments such as 5-FluoroUracil (5-FU) often lead to non-adhesion from patients and thus to treatment failure. In regards to 5-FU treatment, these local reactions are related to the pharmacological action of the molecule. The current therapeutic challenge is to reduce the local reactions induced by 5-FU without interfering with its efficacy, in particular by the use of an emollient cream. The aim of the present study is to investigate how the use of an emollient, namely Dexeryl, could improve the local skin reactions occurring during 4 weeks of a 4% 5-FU treatment.

Conditions

  • Actinic Keratoses

Interventions

  • 5-fluorouracil 4% (Tolak)Drug

    Application of Tolak once daily in the evening for 4 weeks

  • DexerylDevice

    Application of Dexeryl once daily in the morning for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local Skin Reaction (LSR) total scoreTime frame: at 4 weeks or Last Observation Carried Forward (LOCF)

Locations

27 sites in 4 countries. Site status is shown where the registry gives one.

  • Private practice Maire

    Arras, France

  • Chu de Nantes Hôtel-Dieu

    Nantes, France

  • CHU Pau

    Pau, France

  • CHU Poitiers

    Poitiers, France

  • CHU St Etienne Hopital Nord

    Saint-Etienne, France

  • Kath. Klinikum Bochum St. Josef-Hospital

    Bochum, Germany

  • MVZ Dermatologisches Zentrum Bonn GmbH

    Bonn, Germany

  • Private practice Quist

    Bretzenheim, Germany

  • Private Practice Kurzen

    Freising, Germany

  • Dermatologikum Hamburg

    Hamburg, Germany

  • Hautarztpraxis

    Witten, Germany

  • CentroDerm Clinic

    Witten, Germany

  • Uni Clinic Brescia

    Brescia, Italy

  • Uni Clinic Catania

    Catania, Italy

  • Uni Clinic L'Aquila

    Coppito, Italy

  • Policlinico San Martino

    Genova, Italy

  • University of Messina

    Messina, Italy

  • Uni Clinic Modena

    Modena, Italy

  • NAPLES VANVITELLI UNIVERSITI (Federico II Hospital)

    Naples, Italy

  • Azienda Unità Sanitaria Locale - IRCCS

    Reggio Emilia, Italy

  • Catholic University Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

  • Sapienza University of Rome - Polo Pontino

    Terracina, Italy

  • Centre medic Congres

    Barcelona, Spain

  • Hospital Alfredo Espinosa

    Bilbao, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Instituto Valenciano de Oncología,

    Valencia, Spain

  • Hospital Marina Baixa

    Villajoyosa, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.